3 drugmakers settle lawsuit claiming they stifled generic competition

Three generic drugmakers — Teva Pharmaceuticals, Mylan and Ranbaxy —  will pay $65.9 million to settle claims that they engaged in a scheme promoting anticompetitive behavior, according to Reuters.

The lawsuit claims that the three drugmakers participated in pay-for-delay deals to prevent the release of a generic, cheaper version of the wakefulness drug Provigil.

The settlement resolves a class-action lawsuit brought by health plans and other indirect purchasers of Provigil.

Read the full report here.


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars